Current clinical issues in testicular germ cell tumour management include limited sensitivity and specificity of conventional biomarkers and, therefore, reliance on serial CT imaging in follow-up monitoring, as well as poor ability to risk stratify patients. Circulating microRNAs are likely to help overcome these challenges and, importantly, could offer cost savings to health-care systems.
This is a preview of subscription content, access via your institution
Access options
Access Nature and 54 other Nature Portfolio journals
Get Nature+, our best-value online-access subscription
$29.99 / 30 days
cancel any time
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Charytonowicz, D. et al. A cost analysis of non-invasive blood-based microRNA testing versus CT scans for follow-up in patients with testicular germ cell tumors. Clin. Genitourin. Cancer https://doi.org/10.1016/j.clgc.2019.03.015 (2019).
Dieckmann, K. P. et al. Serum levels of microRNA-371a-3p (M371 test) as a new biomarker of testicular germ cell tumors: results of a prospective multicentric study. J. Clin. Oncol. 37, 1412–1423 (2019).
Murray, M. J. & Coleman, N. MicroRNA dysregulation in malignant germ cell tumors: more than a biomarker? J. Clin. Oncol. 37, 1432–1435 (2019).
Murray, M. J., Huddart, R. A. & Coleman, N. The present and future of serum diagnostic tests for testicular germ cell tumours. Nat. Rev. Urol. 13, 715–725 (2016).
Palmer, R. D. et al. Malignant germ cell tumors display common microRNA profiles resulting in global changes in expression of messenger RNA targets. Cancer Res. 70, 2911–2923 (2010).
Murray, M. J. et al. Identification of microRNAs from the miR-371~373 and miR-302 clusters as potential serum biomarkers of malignant germ cell tumors. Am. J. Clin. Pathol. 135, 119–125 (2011).
Gillis, A. J. et al. Targeted serum miRNA (TSmiR) test for diagnosis and follow-up of (testicular) germ cell cancer patients: a proof of principle. Mol. Oncol. 7, 1083–1092 (2013).
Hindson, C. M. et al. Absolute quantification by droplet digital PCR versus analog real-time PCR. Nat. Methods 10, 1003–1005 (2013).
Murray, M. J. et al. A pipeline to quantify serum and cerebrospinal fluid microRNAs for diagnosis and detection of relapse in paediatric malignant germ-cell tumours. Br. J. Cancer 114, 151–162 (2016).
Murray, M. J. et al. “Future-proofing” blood processing for measurement of circulating miRNAs in samples from biobanks and prospective clinical trials. Cancer Epidemiol. Biomarkers Prev. 27, 208–218 (2018).
Acknowledgements
The authors thank St. Baldrick’s Foundation (reference 358099) and the Isaac Newton Trust (reference 15.40f) for grant funding and are grateful for financial support from the Max Williamson Fund and from C. Hodson and A. Hodson, in memory of their daughter Olivia.
Author information
Authors and Affiliations
Corresponding authors
Ethics declarations
Competing interests
N.C. declares royalties from patents licensed by Becton Dickinson from Cancer Research Technology (UK) relating to the use of minichromosome maintenance proteins as biomarkers for cancer diagnosis. M.J.M. declares no competing interests.
Rights and permissions
About this article
Cite this article
Murray, M.J., Coleman, N. Can circulating microRNAs solve clinical dilemmas in testicular germ cell malignancy?. Nat Rev Urol 16, 505–506 (2019). https://doi.org/10.1038/s41585-019-0214-2
Published:
Issue Date:
DOI: https://doi.org/10.1038/s41585-019-0214-2
